文献速递泌尿男性生殖肿瘤

PIK3CA突变是前列腺癌的遗传驱动因素,与PTEN缺失协同加速进展和去势抵抗性生长

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.
PubMed 文献 · Cancer Discov · 2018-03-26

本研究发现PIK3CA突变/扩增与前列腺癌患者生存期差相关,小鼠实验表明Pik3caH1047R突变可导致侵袭性前列腺癌,并且PIK3CA突变与PTEN缺失共存可协同加速疾病进展和去势抵抗性前列腺癌(CRPC)的发生,提示PIK3CA突变是预后指标并可能成为治疗靶点。

要点

  • PIK3CA突变/扩增与前列腺癌患者生存期差相关。
  • 小鼠中Pik3caH1047R突变引起p110α依赖的侵袭性前列腺癌。
  • PIK3CA突变与PTEN缺失协同加速进展和去势抵抗性前列腺癌。

核心结论

  • PIK3CA突变是前列腺癌的遗传驱动因素,与PTEN缺失协同加速进展和去势抵抗性生长。

研究设计与样本

  • 采用遗传学方法在小鼠前列腺上皮中突变Pik3ca,并结合患者数据进行分析。

主要发现

  • PIK3CA突变/扩增与前列腺癌患者生存期差相关。
  • Pik3caH1047R突变导致p110α依赖的侵袭性前列腺癌。
  • PIK3CA突变与PTEN缺失共存可协同加速疾病进展,通过AKT-mTORC1/2过度激活。
  • 同时具有Pik3ca突变和Pten缺失的小鼠发生de novo CRPC。

临床怎么用

  • PIK3CA突变可作为前列腺癌的预后指标。
  • PIK3CA突变与PTEN缺失的协同关系可能为克服去势/PI3K-AKT-mTORC1/2抑制剂耐药提供新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic alterations that potentiate PI3K signaling are frequent in prostate cancer, yet how different genetic drivers of the PI3K cascade contribute to prostate cancer is unclear. Here, we report PIK3CA mutation/amplification correlates with poor survival of patients with prostate cancer. To interrogate the requirement of different PI3K genetic drivers in prostate cancer, we employed a genetic approach to mutate Pik3ca in mouse prostate epithelium. We show Pik3caH1047R mutation causes p110α-dependent invasive prostate carcinoma in vivo Furthermore, we report that PIK3CA mutation and PTEN loss coexist in patients with prostate cancer and can cooperate in vivo to accelerate disease progression via AKT-mTORC1/2 hyperactivation. Contrasting single mutants that slowly acquire castration-resistant prostate cancer (CRPC), concomitant Pik3ca mutation and Pten loss caused de novo CRPC. Thus, Pik3ca mutation and Pten deletion are not functionally redundant. Our findings indicate that PIK3CA mutation is an attractive prognostic indicator for prostate cancer that may cooperate with PTEN loss to facilitate CRPC in patients.Significance: We show PIK3CA mutation correlates with poor prostate cancer prognosis and causes prostate cancer in mice. Moreover, PIK3CA mutation and PTEN loss coexist in prostate cancer and can cooperate in vivo to accelerate tumorigenesis and facilitate CRPC. Delineating this synergistic relationship may present new therapeutic/prognostic approaches to overcome castration/PI3K-AKT-mTORC1/2 inhibitor resistance. Cancer Discov; 8(6); 764-79. ©2018 AACR.See related commentary by Triscott and Rubin, p. 682This article is highlighted in the In This Issue feature, p. 663.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Pearson HB, Li J, Meniel VS, et al. Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discov. 2018. PMID: 29581176. doi:10.1158/2159-8290.CD-17-0867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。